What EBITDA multiple can I get for my dental practice?

Ask ten owners what a dental practice EBITDA multiple should be and you will hear ten different numbers, usually sourced from a friend of a friend who sold at the top. Here is what the deal activity keeps confirming: the multiple is not a market price. It is a judgment about your future. Two practices with identical earnings can walk away from the same buyer with very different offers, because the buyer is not purchasing what you earned last year. They are purchasing confidence that the earnings continue, and grow, after you hand over the keys. What follows is a walk through every lever that moves that judgment, drawn from audit data spanning more than 201,000 US practices.

What EBITDA multiple can you actually expect for your dental practice?

There is a number everyone quotes and a number that actually happens. In general conversation, single-location practices tend to trade somewhere in the low to mid single digits of EBITDA, and platform-scale groups command meaningfully more. Treat those figures as folklore, not physics. Nobody can promise you a multiple, and anyone who does is selling something. What the deal patterns make clear is that the range is wide, and where you land inside it is not random. The spread between a tired offer and a strong one on the same earnings can be worth more than a decade of clinical production. That spread is decided by things that never appear on your P&L: how discoverable your locations are, how dependent the revenue is on your hands, how defensible your patient flow looks to an analyst who has never met you. Your practice already occupies a position inside that range. You just have not been shown where. The rest of this guide walks through each lever the buyers weigh, so you can read your own practice the way an acquisition committee will read it, before they do.

Why do two practices with identical EBITDA sell at different multiples?

Because the multiple prices risk, not history. When an acquisition analyst opens your file, trailing EBITDA is the starting point, not the conclusion. Every question after it is a version of the same question: what could make this number shrink once the owner is gone? Three discounts show up over and over:

• Owner-concentrated production: when most dollars run through the seller's hands, the earnings walk out the door with you, and the model says so.
• Untransferable patient flow: new patients arriving through personal relationships nobody can hand over read as a stream with an expiry date.
• Unexplained revenue: a patient base you cannot trace to a source is a patient base a buyer cannot trust to refill.

None of these arrive as line items. They arrive as a lower multiple, dressed up as a market rate. The practices that command the top of the range are not always the biggest earners. They are the ones that leave an analyst with the fewest unanswered questions. Your job before a sale is not to inflate EBITDA. It is to remove the reasons a stranger would doubt it.

What is a DSO acquirer actually buying from you?

Not your chairs, not your CBCT, not the buildout you agonised over. Equipment is a rounding error in these deals. What an acquirer is buying is a stream of future patient decisions: the probability that people in your market keep choosing your locations after your involvement ends, multiplied by what those patients are worth. That is why diligence teams skim your asset list and go deep on your patient flow, your referral concentration, and your local reputation. They are underwriting behaviour, not property. Understand this and the whole negotiation reorders itself. Everything that makes patient behaviour predictable, a strong practice brand, dominant local visibility, recall systems that run without heroics, adds turns to your multiple. Everything that makes it fragile subtracts them. The buy side has industrialised this read; the patterns across the whole segment are tracked in the acquisition market intelligence hub, and they all point the same direction. Every dollar of your EBITDA is being sorted into two buckets: dollars that survive your departure and dollars that do not. Only the first bucket earns a multiple. Preparing for a sale is really just the work of moving dollars from the second bucket into the first.

How much does owner dependence pull your multiple down?

More than any other single factor, and more than most owners can hear. Buyers have a phrase for revenue that depends on you personally: personal goodwill. It is the portion of your earnings tied to your hands, your chairside manner, your relationships. Enterprise value is the portion tied to the practice as a system: its brand, its patient flow, its team, its position in the community. Acquirers pay multiples for enterprise value. They discount personal goodwill sharply, because they cannot buy you, only your practice. Run the test tonight. When your patients recommend the practice, do they name it, or do they name you? If the answer is you, your earnings are loyal to a person who is planning to leave, and every analyst who models the deal will price that in. The fix is not clinical. Associates can be hired. The fix is positional: the practice itself has to become the thing patients search for, find, and trust, independent of whose name is on the licence. Practices that make that shift early stop selling a job and start selling an asset. The multiple follows the asset, every time the file gets read.

Does your procedure mix change what an acquirer will pay?

Quietly, yes, because mix is a proxy for durability and growth. Implant demand is compounding at 8.5 percent a year with a $4,500 average case value. If implants are a growing share of your production, you are showing a buyer a revenue line that rises on its own demographics, and your model gets built with a growth curve instead of a flat line. Cosmetic runs at 6.8 percent annual growth and $3,800 a case; ortho grows 5.1 percent at $5,500. Each of those lines in your mix is a claim about the future you are selling. But mix only earns a premium if the pipeline feeding it is visible. Here is the figure that should reframe your whole diligence prep: AI-referred patients book high-value treatment at 2 to 3 times the rate of patients from other channels. Your implant and aligner growth story is only credible if a buyer can see where those patients come from, and increasingly they come from engines that either recommend your practice or have never heard of it. A high-value mix with an invisible pipeline reads as luck. The same mix with a visible pipeline reads as a machine.

How does your patient discovery engine show up in diligence?

As the difference between a practice that happens to be busy and a practice that is built to stay busy. The average solo practice leaves about $147,000 a year in unrealised revenue, demand that exists in its market and never reaches its chairs. Across a ten-location group, you can do that multiplication yourself, and so will the buyer, in whichever direction your visibility points. The mechanics are stark. Practices with a complete Google Business Profile earn up to 7 times more clicks than practices with incomplete listings, and 82 percent of dental searches end in a Maps interaction. The map pack is not a channel. It is the front door, and diligence teams walk through it before they ever call your broker. An analyst can see your review velocity, your profile completeness, your ranking against the practice two miles away, all from a laptop, all before the letter of intent. This is why sellers who treat visibility as an afterthought get read as riskier than they are, and why understanding what a dental positioning expert changes first matters years before you take a meeting. Your front door is already being inspected.

What does AI search visibility have to do with your EBITDA multiple?

Everything a buyer means when they say durable. Patients now run 432,000 dental searches a month through AI engines, and those engines answer with a shortlist, not ten blue links. The Dental Index national practice audit found that 70 percent of practices are completely invisible to those engines: not ranked low, absent. If your locations sit inside that 70 percent, a growing share of your future patient flow is being routed to competitors before anyone compares you, and a sophisticated acquirer either knows that already or will very soon. The readiness numbers say most sellers are exposed: the average practice scores below 40 out of 100 on AI readiness, and only 8 percent score above 65. Sit with what that means for your exit. The thing you are selling is future patient demand, and the fastest-growing discovery channel in dentistry cannot see the asset. Practices in the visible 8 percent are not just collecting patients today. They walk into negotiations with proof that their revenue stream is wired into where discovery is going, not where it has been. That proof is exactly what a multiple pays for.

Can your team hold the earnings together after you leave?

A buyer will ask, because payroll is where deals quietly die. Right now 33.9 percent of practices are actively recruiting hygienists. That is a third of the market competing for the same clinicians, and it means your staffing stability is a differentiator whether you intended it or not. Your hygiene reappointment engine is a revenue annuity, and an acquirer models it that way: if your hygienists leave in the transition, recall collapses, and the EBITDA they underwrote evaporates in two quarters. So they probe. Tenure, pay structure, whether the team is loyal to the practice or to you personally, whether the practice's reputation makes it a place clinicians want to join or a place they settle for. This is where positioning does quiet work owners rarely credit. A practice that is visibly the leading name in its market recruits more easily, retains longer, and survives an ownership change with its schedule intact. A practice that is invisible fights for every hire at a premium. When you present a stable, tenured team inside a practice whose name carries weight locally, you are not showing a buyer a staff list. You are showing them insurance on their own model.

Is the consolidation window working for you or against you?

Both, depending on when and how you arrive at it. DSOs now hold 32 percent of a $179.4 billion market, and the arithmetic of that share is the single most important context for your exit. Consolidators need acquisitions to keep growing, which sustains demand for groups like yours. But as their share climbs, they get more selective, because they have seen hundreds of files and know exactly which risks repeat. Early in a consolidation wave, buyers pay for potential. Late in the wave, they pay for proof. You are selling into the middle of that shift. The practices getting rewarded now are the ones that look like what the platforms already own: multi-clinician, systematised, discoverable, growing in the high-value categories. The ones getting discounted are the ones that look like work: owner-dependent, invisible online, staffed by a thread. Neither the window closing nor the window staying open is the real story for you. The real story is that the bar for a premium multiple rises every quarter this consolidation runs, and the sellers who treat that as a deadline for getting their story straight consistently walk in better prepared than the ones who treat it as background noise.

What story does your practice tell when you are not in the room?

That is the question every diligence process is really asking, because you will not be in the room when your file is read. An analyst you have never met will condense decades of your work into a one-page picture, built partly from your numbers and partly from what the public internet says about you. You do not get to narrate that picture. It assembles itself from what is checkable, and the two versions of it read very differently:

The Dental Index national practice audit · 2026

Every row in that table can be verified from a laptop before anyone calls you. The left column does not describe worse dentistry. It describes a practice whose story is being told by its absence, and absence always reads as risk. The story has to already be true, in the places buyers look, before they look.

What can you change in the next 12 to 24 months?

More than you think, because most of what drags a multiple down is positional, not clinical, and positional problems move faster than clinical ones. You cannot triple EBITDA in eighteen months without breaking something. You can make the EBITDA you already have believable. That means shifting patient loyalty from your name to the practice's name, location by location. It means closing the visibility gap while most of your competitors are still ignoring theirs, because joining the small visible minority is worth more than being average at everything else. It means letting your high-value lines, the implant and aligner cases your future buyer wants to underwrite, show up where engines and analysts can both see them. None of this guarantees a number, and you should walk away from anyone who promises one. What it does is remove discounts, one by one, until the offer you receive reflects the practice you actually built instead of the risks a stranger could not rule out. Sellers who start this work two years out are not gaming the system. They are doing the buyer's diligence first, on themselves, while there is still time to change the answer.

Remember the group from the top of this piece. The version of Marcus who takes the first offer accepts a discount for questions he could have answered. The version who spends two years making his practices findable, transferable, and visibly growing walks into the same room with a different file. Same chairs. Same hands. Different multiple. That is the whole argument of this data guide in one line: your multiple is your positioning, priced. And positioning is not abstract. It is whether the engines recommend you, whether your Google profile outranks the practice two miles away, whether a stranger researching your market finds you first. Every one of those is measurable today, which means every one of them can be fixed before a buyer sees it. The sellers who check first never have to negotiate against their own invisibility.